Sitagliptin
Brand Names: Januvia, Zituvio
Methodology & AI Transparency ⓘ
Sitagliptin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage januvia: ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- 2 Real-world patient consensus: Tracked across 13 patient dosage logs with a 90% satisfaction benchmark (RxCUI 665036).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $46.39 wholesale mail-order against $113.66 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Sitagliptin): headache (11%), arthralgia (5%), nasopharyngitis (5.5%).
Ask our AI Specialists anything about Sitagliptin
Sitagliptin Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage januvia: ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes ( 1 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1 , 5.1 ) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes.
12.1 Mechanism of Action Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4.
Pharmacokinetic profiling of Sitagliptin demonstrates an elimination half-life of 12.4 hours terminal elimination (Sitagliptin SPL) with F ≈ 61%–73% systemic availability after standard oral Sitagliptin administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across sitagliptin regimens, reaching clinical onset within time to peak concentration spans 1 to 3 hrs under sitagliptin maintenance.
Titration schedules for Sitagliptin (50 mg/1 Tablet, Film Coated → 50 mg/1 Tablet → 100 mg/1 Tablet, Film Coated → 25 mg/1 Tablet, Film Coated → 25 mg/1 Tablet) require excluding history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.; history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema ( 5.5 , 6.2 ); real-world patient logs highlight headache (11% of reports), nausea (8.6% of reports), nasopharyngitis (5.5% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Sitagliptin (dipeptidyl peptidase 4 inhibitor).
Unstandardized herbal extracts may interact pharmacodynamically with Sitagliptin maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.
- History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema ( 5.5 , 6.2 )
Logged Side-Effect Incidence (13 Reports)
Sitagliptin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sitagliptin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sitagliptin added to stable insulin therapy with or without metformin in Chinese: What a 467-Participant Study Found After 24 weeks, sitagliptin added to stable insulin therapy (±metformin) was generally well tolerated and improved blood sugar control in Chinese patients with type 2 diabetes. Journal of diabetes investigation • 2017-05-15 • Randomized Controlled Trial | N = 467 | 93/100 | PMID 27740719 ↗ |
| New Insights on Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in: What a 466-Participant Study Found Among 1864 patients randomized (mean age, 58 [SD, 10] years; mean baseline HbA1c, 8.3% [SD, 0.9%]; mean body mass index, 32.5 [SD, 6.4]; n=879 [47.2%] women), 1758 (94.3%) completed the trial and 298 prematurely discontinued... JAMA • 2019-04-16 • Phase III Randomized Trial | N = 466 | 93/100 | PMID 30903796 ↗ |
| New Insights on Dapagliflozin is effective as add-on therapy to sitagliptin with or without: What a 432-Participant Study Found These results suggest that in patients with type 2 diabetes, inadequately controlled on sitagliptin with or without metformin, add-on treatment with dapagliflozin provides additional clinical benefit and is well tolerated. Diabetes care • 2014-01-15 • Randomized Controlled Trial | N = 432 | 93/100 | PMID 24144654 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of combining empagliflozin in people with type 2 diabetes These results suggest that getting both at the same time of empagliflozin safely improves blood sugar control in Korean patients with T2DM uncontrolled by sitagliptin and metformin. Diabetes, obesity & metabolism • 2026-03-15 • Phase III Randomized Trial | N = 172 | 88/100 | PMID 41417560 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks. Diabetes, obesity & metabolism • 2026-06-15 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 41883295 ↗ |
Sitagliptin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $10.0363/unit (~$301.09/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $46.39 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $113.66 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $53.35 / mo | View logs ↓ |
Sitagliptin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sitagliptin RxNorm Concept ID | 665036 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $10.0363 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $113.66 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $46.39 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sitagliptin Patient Community, Cohort Filters & Dosage Logs
Deterministic Sitagliptin reference combining NIH RxNorm (665036), Medicaid NADAC ($10.0363/unit), and anonymous cohort outcomes (90% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sitagliptin community threads and patient logs by age, biological sex, dosage, and treatment duration.